'Article 1 big fish' Celltrion Healthcare, KOSDAQ approved ... Listed next month

[Korea goyounghun financial newspaper reporter] said 15 days has approved the preliminary examination Celltrion Healthcare Korea Exchange KOSDAQ Listed headquarters after deliberation by the Council the day before the KOSDAQ IPO.

Celltrion Healthcare is aiming for IPO next month to apply for a preliminary examination traded exchange in December last year. Sponsor UBS is treated with MAS.

The main shareholders are the Chairman Seo Jung-jin et al. (44.12%) 8 holds a stake of 45.23%. 8193 ~ 1 billion public offering is expected to amount one trillion 97 billion, 10 003 10 000 3300-4 going issued share plans have been observed at 1000 won.

Celltrion Healthcare last year as the global biopharmaceuticals company specializing in distribution of exclusive bio-pharmaceuticals production Celltrion sales posted a 757.7 billion won. The numbers also increased during the same period net profit 329.7% YoY to 122.9 billion won. It shows the current RAM and exclusive island, huh jyuma, teuruk Shima products, including biosimilars, which are strong.



Financial Daily Economic News FNTIMES - unauthorized reproduction for commercial purposes in accordance with the Copyright Act, No copying, distribution,
Copyright ⓒ Korea's financial newspaper & FNTIMES.com